# Pharmacology Asthma & COPD
<!-- toc -->
# Big Picture
**Problem in Asthma & COPD**
* Asthma: Triggers + reversible Bronchoconstriction + Airway inflammation
* COPD (Emphysema & Bronchitis): Airway obstruction >> inflammation

**How to fix?**
* Bronchodilation
  * Activate Sympathetic Nervous System (B2): **SABA & LABA**
  * Inhibit Parasympathetic Nervous System: **Muscarinic Antagonists**
  * Increase cAMP— Bronchodilation: **Theophylline**
* Decrease inflammation
  * Inhibit Arachidonic Acid/Prostaglandins synthesis: **Oral/lnhaled Corticosteroids**
  * Block Leukotrienes: **Montelukast**
* Minimize triggers
  * Block IgE from binding to mast cell: **Omalizumab**
  * Stabilize mast cells: **Cromolyn**

# Beta Agonists
## Short Acting Beta 2 Agonists (SABA):
**Albuterol**

**MOA**: Beta2 agonist relaxes bronchial smooth muscle

**Use**: Acute Asthma and COPD exacerbation due to its short half life

**Route**: Inhaled & Oral

**SE:**
* **Anxiety & Tremor**: B2 on vasculature
* **Arrhythmias**: B1 on heart
* **Hypokalemia**: Beta receptors on Na-K ATPase pump- Drives K into cell

## Long Acting Beta 2 Agonists (LABA):
**Formoterol & Salmeterol**

**MOA**: Same as SABA

**Use:**
* Chronic Asthma NOT acute asthma
* Chronic COPD
* Used in combination with Inhaled Corticosteroid (ICS)- **Never used alone
because of increased risk of death in clinical studies**

**Route**: Inhaled

SE: Same as SABA but to lesser extent

# Muscarinic Antagonists
## Short Acting: Ipratropium
**MOA**: Block muscarinic receptors preventing parasympathetic effect leading to bronchodilatLon

**Use**: Combined with Albuterol for Acute Asthma and COPD exacerbation

**Route**: Inhaled

SE: Minimal

## Long Acting: Tiotropium
MOA: Same as Ipratropium

**Use:**
* Chronic COPD treatment
* Less effective in Chronic Asthma Treatment

**Route: Inhaled**

# Corticosteroids
## Inhaled Corticosteroids- ICS (Budesonide & Fluticasone)
MOA:
* Inhibit Phospholipase A2 (Beginning of inflammation pathway)
* Leading to inhibition of prostaglandins/interleukins decreasing inflammation

Use: **Chronic Asthma** and COPD treatment-Not used for acute management-Combined with LABA

**Inhaled SE**
* Oral Candidiasis/Thrush: Patients are instructed to rinse mouth after use
* Hoarseness: Vocal cords irritation

## Systemic Corticosteroids (Prednisone & Methylprednisolone)
MOA:
* Inhibit Phospholipase A2 (Beginning of inflammation pathway)
* Leading to inhibition of prostaglandins/interleukins decreasing inflammation

Use: Acute Asthma and COPD exacerbations- Effect is not evident immediately

### Systemic SE
**CV**
* **Salt/H20 Retention**: Mimics aldosterone effect

**Endocrine**
* **Cushing Syndrome**: Redistribution of body fat/Lipodystrophy
* **Hyperglycemia**: Increases insulin resistance
* **Adrenal Insufficiency (HPA Axis Suppression)**
  * For treatment longer > 10 days - Patients will need dose tapered
  * Presents as hypotension and shock during stressful situations (i.e. surgery, infection)

**GI**
* **Peptic Ulcers**: Decrease Gl protective prostaglandin release

**Neuro: Psychosis**

**Eye: Cataracts**

**Immuno:**
  * **Poor wound healing**: Decrease fibroblast activity
  * **Immunodeficiency**: Block IL2, prostaglandins, leukotriene synthesis, Decrease WBC adhesion

**Bone**
* **Osteoporosis**: Inhibit Osteoblasts
* **Avascular necrosis of femoral head**

# Others
## Anti-Leukotrienes (Montelukast & Zileuton)

*Leukotrienes cause inflammation and increased bronchial constriction*
**MOA:**
* **Montelukast**: Block Leukotriene receptor
* **Zileuton**: 5-Lipoxygenase inhibitor- Block conversion of arachidonic acid to leukotrienes

Use:
* Aspirin Induced Asthma
  * Aspirin blocks COX1&2 blocking prostaglandins synthesis leading to increased leukotrienes synthesis
* Exercise induced Asthma

SE: Minimal

## Methylxanthines (Theophylline, Caffeine)- Oral
**MOA**: Phosphodiesterase inhibitor---> Increase cAMP— Bronchodilation

**Use:** Last line in Chronic Asthma and COPD due to its narrow therapeutic index

**SE**
* CNS Stimulation (**Seizures**, Nervousness, insomnia)
* Cardiac Stimulation (Tachycardia, Arrhythmias)
* Metabolized by CYP 450 enzymes- Drug interactions (i.e. macrolides increase concentration)

## Anti-IgE (Omalizumab)- Intravenous
MOA: Binds unbound serum IgE-Prevents IgE binding to FceR1 receptor on mast cell-Prevent degranulation

Use: Refractory allergic asthma with High IgE levels
## Cromolyn- Inhaled
MOA: Stabilizes mast cell

Use: Asthma prophylaxis
## N-Acetylcysteine- Inhaled
Liquefies thick mucus in COPD- Relieves congestion

# Asthma Treatment Summary
## Acute Asthma Attack
1. Secure Airway- Intubation if necessary
2. **Nebulized Albuterol**
3. **Oral/IV Steroid** (Prednisone/Methylprednisolone)-*Not the First Priority*
4. +/- Ipratropium
5. +/- IV magnesium
* Inhibit smooth muscle contraction
* Inhibit Ach release

## Chronic Asthma
**Step wise approach**

1. **Intermittent Asthma**: SABA prn
2. **Mild Persistent**: Low dose ICS + SABA
3. **Moderate Persistent**: Medium dose ICS+LABA
4. **Severe Persistent**: High dose ICS+LABA +/- systemic steroids
5. **Refractory**: Theophylline
6. **Allergic Asthma**: Anti-Leukotrienes, Omalizumab

# COPD Treatment Summary
## Acute COPD Exacerbation

1. Secure Airway- Intubation if necessary
2. **Nebulized Albuterol combined with Ipratropiuin**
3. **Oral/lV Steroids (prednisone/Methylprednisolone)**
4. ***Using High levels of O2 in acute COPD exacerbation may lead to respiratory failure***
* Respiratory drive in these patients is dependent on Hypoxemia rather than hypercapnia
* Relieving hypoxemia by high O2 levels decrease respiratory drive

## Chronic COPD Treatment
* **Continuous 02**: **Only therapy proven to decrease mortality in advanced stages of COPD**
* **Inhaled ICS + LABA (Fluticasone + Salmeterol)**: Reduce exacerbations, hospitalizations and mortality
* **Long Acting antimuscarinics (Tiotropium)**: Improve symptoms and quality of life
* **Theophylline**: Advanced COPD
* **Mucolytics**: Symptom relief only
